432.17
2.35 (0.55%)
| Previous Close | 429.82 |
| Open | 432.43 |
| Volume | 1,110,066 |
| Avg. Volume (3M) | 1,495,364 |
| Market Cap | 110,804,353,024 |
| Price / Earnings (TTM) | 30.39 |
| Price / Earnings (Forward) | 22.37 |
| Price / Sales | 9.40 |
| Price / Book | 6.25 |
| 52 Weeks Range | |
| Earnings Date | 3 Nov 2025 |
| Profit Margin | -8.91% |
| Operating Margin (TTM) | 37.22% |
| Diluted EPS (TTM) | -3.80 |
| Quarterly Revenue Growth (YOY) | 3.00% |
| Quarterly Earnings Growth (YOY) | -41.20% |
| Total Debt/Equity (MRQ) | 10.00% |
| Current Ratio (MRQ) | 2.65 |
| Operating Cash Flow (TTM) | -980.30 M |
| Levered Free Cash Flow (TTM) | 2.63 B |
| Return on Assets (TTM) | 11.77% |
| Return on Equity (TTM) | -5.64% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Mixed | Mixed |
| Biotechnology (Global) | Mixed | Mixed | |
| Stock | Vertex Pharmaceuticals Incorpor | Bearish | Bearish |
AIStockmoo Score
| Analyst Consensus | -0.5 |
| Insider Activity | -5.0 |
| Price Volatility | 2.0 |
| Technical Moving Averages | 2.5 |
| Technical Oscillators | 0.5 |
| Average | -0.10 |
|
Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio for cystic fibrosis, where Vertex therapies remain the standard of care globally. Vertex has diversified its portfolio through Casgevy, a gene-editing therapy for beta thalassemia and sickle-cell disease. Additionally, Vertex is evaluating small-molecule inhibitors targeting acute and chronic pain using nonopioid treatments, and small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| Investment Style | Large Value |
| % Held by Insiders | 0.15% |
| % Held by Institutions | 97.64% |
| 52 Weeks Range | ||
| Price Target Range | ||
| High | 575.00 (Citigroup, 33.05%) | Buy |
| Median | 456.00 (5.51%) | |
| Low | 414.00 (Barclays, -4.20%) | Hold |
| Average | 477.11 (10.40%) | |
| Total | 5 Buy, 4 Hold | |
| Avg. Price @ Call | 410.17 | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| UBS | 07 Nov 2025 | 546.00 (26.34%) | Buy | 409.47 |
| Barclays | 04 Nov 2025 | 414.00 (-4.20%) | Hold | 421.67 |
| RBC Capital | 04 Nov 2025 | 415.00 (-3.97%) | Hold | 421.67 |
| Stifel | 04 Nov 2025 | 445.00 (2.97%) | Hold | 421.67 |
| Morgan Stanley | 10 Oct 2025 | 438.00 (1.35%) | Hold | 407.79 |
| JP Morgan | 08 Oct 2025 | 530.00 (22.64%) | Buy | 421.15 |
| Citigroup | 02 Oct 2025 | 575.00 (33.05%) | Buy | 408.85 |
| Leerink Partners | 25 Sep 2025 | 456.00 (5.51%) | Buy | 381.87 |
| Evercore ISI Group | 11 Sep 2025 | 475.00 (9.91%) | Buy | 397.37 |
| Name | Avg. Buy ($) | Avg. Sell ($) | Net Quantity | Net Value ($) |
|---|---|---|---|---|
| ATKINSON EDWARD MORROW III | - | 434.02 | -2,500 | -1,085,050 |
| CARNEY LLOYD | - | 421.03 | -800 | -336,824 |
| LEIDEN JEFFREY M | - | 437.15 | -53,604 | -23,432,989 |
| Aggregate Net Quantity | -56,904 | |||
| Aggregate Net Value ($) | -24,854,863 | |||
| Aggregate Avg. Buy ($) | - | |||
| Aggregate Avg. Sell ($) | 430.73 | |||
| Name | Holder | Date | Type | Quantity | Price | Value ($) |
|---|---|---|---|---|---|---|
| CARNEY LLOYD | Director | 19 Nov 2025 | Disposed (-) | 800 | 421.03 | 336,824 |
| ATKINSON EDWARD MORROW III | Officer | 17 Nov 2025 | Automatic sell (-) | 2,500 | 434.02 | 1,085,050 |
| LEIDEN JEFFREY M | Officer | 14 Nov 2025 | Automatic sell (-) | 53,604 | 437.15 | 23,432,989 |
| LEIDEN JEFFREY M | Officer | 14 Nov 2025 | Option execute | 53,604 | - | - |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2025 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |